6,347 trials (keyword fallback)
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Leukemia · Myelodysplastic Syndromes
Primary: Number of Patients Experiencing Regimen-related Toxicity Events in Study Population — 2; 5 participants
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Time to Failure — 16; 13 Days
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission
Primary: Time to Neutrophil Engraftment — 20.0; 22.0 days
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Proportion of Patients With Clinical Response — 0.32; 0.27; 0.46; 0.17 Proportion of patients
Acute Lymphoblastic Leukemia (ALL)
Primary: Complete Remission Plus Complete Remission Without Full Platelet Recovery (CR + CRi) — 13 participants
Leukemia
Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants
Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Overall Survival — 34 Participants
Leukemia · Lymphoma
Primary: Complete Remission (CR) — 50; 50; 14; 11 participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Leukemia
Primary: Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) — 1; 2; 0; 2 participants
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Relapse Incidence — 18 Participants
Leukemia
Primary: Maximum Tolerated Dose of Intensity-modulated Radiotherapy (Phase I) — 2000 cGy